← Leaderboards
Peter G Rose
Case Western Reserve University
$19,199
Attributed
$19,199
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$19,199 · 3
By mechanism
M01$19,199 · 3
Top collaborators
No co-investigators on record.
Most similar at Case Western Reserve University
Same institution · by research overlap
- Scot C Remick$11,938,221
- Jinming Gao$19,330,906
- Hasan Mukhtar$12,132,209
- Beth A Overmoyer$760,943
- Constance G Visovsky$2,933,807
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHuman Therapy EvaluationOvary NeoplasmsNeoplasm /Cancer ChemotherapyDrug Screening /EvaluationClinical ResearchDrug Administration Rate /DurationPharmacokineticsAntineoplasticsCis Platinum CompoundCombination ChemotherapyFemaleNeoplasm /Cancer Relapse /RecurrencePaclitaxelQuality Of LifeWomen'S HealthNeoplasm /Cancer PharmacologyDrug Adverse EffectInjection /InfusionTopotecan
Grant awards (7)
Elinafide--salvage therapy recurrent ovarian carcinoma$0
M01 · FY2002 · RR
Phase II study of VX 710 &paclitaxel in women with ovarian cancer$0
M01 · FY2002 · RR
Phase II study of VX 710 &paclitaxel in women with ovarian cancer$0
M01 · FY2001 · RR
Elinafide--salvage therapy recurrent ovarian carcinoma$0
M01 · FY2001 · RR
TOPOTECAN IN PATIENTS WITH ADVANCED OVARIAN CARCINOMA$19,199
M01 · FY2000 · RR
Phase II study of VX 710 &paclitaxel in women with ovarian cancer$0
M01 · FY2000 · RR
Elinafide--salvage therapy recurrent ovarian carcinoma$0
M01 · FY2000 · RR